Clinical Trials Sponsored by Arcagy Research
Total 39568 results
-
ARCAGY/ GINECO GROUPRecruitingOvarian Cancer Stage IIIC | Ovarian Cancer Stage IV | Ovarian Cancer Stage IIIbFrance
-
ARCAGY/ GINECO GROUPCompleted
-
ARCAGY/ GINECO GROUPCompletedEndometrial CancerFrance
-
ARCAGY/ GINECO GROUPCompleted
-
ARCAGY/ GINECO GROUPCompleted
-
ARCAGY/ GINECO GROUPCompletedOvarian Cancer | Fallopian Tube Cancer | Malignant Tumor of PeritoneumFrance
-
ARCAGY/ GINECO GROUPCompleted
-
ARCAGY/ GINECO GROUPRecruitingOvarian CancerJapan, France
-
ARCAGY/ GINECO GROUPActive, not recruitingOvarian Cancer Stage IVFrance
-
ARCAGY/ GINECO GROUPCompletedOvarian Cancer RecurrentFrance
-
ARCAGY/ GINECO GROUPTerminatedTriple Negative Metastatic Breast CancerFrance
-
ARCAGY/ GINECO GROUPCompletedCervical CancerFrance
-
ARCAGY/ GINECO GROUPTerminated
-
ARCAGY/ GINECO GROUPCompletedPeritoneal Neoplasms | Ovarian Cancer | Fallopian Tube CancerFrance
-
ARCAGY/ GINECO GROUPActive, not recruiting
-
ARCAGY/ GINECO GROUPCompleted
-
ARCAGY/ GINECO GROUPTerminatedFirst Line Metastatic Breast CancerFrance
-
ARCAGY/ GINECO GROUPCompletedOvarian CancerFrance
-
ARCAGY/ GINECO GROUPActive, not recruitingEpithelial Ovarian Cancer | RelapseFrance
-
ARCAGY/ GINECO GROUPCompleted
-
ARCAGY/ GINECO GROUPCompletedMetastatic Breast CancerFrance
-
ARCAGY/ GINECO GROUPCompleted
-
ARCAGY/ GINECO GROUPCompletedMetastatic Breast Cancer
-
ARCAGY/ GINECO GROUPCompletedPancreatic Neoplasms | Biliary Tract NeoplasmsFrance
-
ARCAGY/ GINECO GROUPCompletedBreast Cancer | Neoplasm MetastasisFrance
-
ARCAGY/ GINECO GROUPNovartisCompletedBreast Neoplasms | mTor ProteinFrance
-
ARCAGY/ GINECO GROUPAstraZenecaCompletedFallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal CancerFrance
-
ARCAGY/ GINECO GROUPAstraZenecaActive, not recruiting
-
ARCAGY/ GINECO GROUPAstraZenecaCompletedRelapsed Ovarian Cancers PatientsFrance
-
ARCAGY/ GINECO GROUPNovartisCompleted
-
ARCAGY/ GINECO GROUPPharmaMarCompletedOvarian CancerFrance
-
ARCAGY/ GINECO GROUPGlaxoSmithKlineRecruitingEndometrial CancerFrance, Singapore, Australia
-
ARCAGY/ GINECO GROUPBayerCompleted
-
Institut CurieARCAGY/ GINECO GROUPCompletedBorderline Ovarian TumorsFrance
-
UNICANCERARCAGY/ GINECO GROUP; SOLTI Breast Cancer Research GroupActive, not recruitingER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer | a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI StatusFrance
-
ARCAGY/ GINECO GROUPTesaro, Inc.Completed
-
ARCAGY/ GINECO GROUPTesaro, Inc.Active, not recruitingOvarian Carcinosarcoma | Endometrial CarcinosarcomaFrance
-
UNICANCERSeagen Inc.; ARCAGY/ GINECO GROUPRecruitingMetastatic Breast Cancer With a Isolated Brain ProgressionFrance
-
ARCAGY/ GINECO GROUPRoche Pharma AGCompleted
-
Centre Francois BaclesseARCAGY/ GINECO GROUPActive, not recruitingGerm Cell Tumor | Sex Cord Stromal Tumor | Malignant Non-epithelial Ovarian TumorsFrance
-
ARCAGY/ GINECO GROUPHoffmann-La RocheActive, not recruitingOvarian CancerSpain, Belgium, France, Germany, Austria, Czechia, Israel
-
ARCAGY/ GINECO GROUPPierre Fabre LaboratoriesTerminated
-
ARCAGY/ GINECO GROUPBristol-Myers SquibbActive, not recruiting
-
ARCAGY/ GINECO GROUPRoche Pharma AGCompleted
-
ARCAGY/ GINECO GROUPHoffmann-La RocheTerminated
-
Centre Francois BaclesseARCAGY/ GINECO GROUP; French Cancer Research Hospital ProgramCompletedPlatinum-resistant or Refractory Ovarian CancerFrance
-
ARCAGY/ GINECO GROUPMerck Sharp & Dohme LLCCompletedMetastatic Cancer | Endometrial Cancer | Advanced Cancer | Oncology | Recurrent CancerFrance
-
ARCAGY/ GINECO GROUPMerck Sharp & Dohme LLCRecruitingAddition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT (PembroSCCOHT)Small Cell Ovarian CarcinomaFrance
-
ARCAGY/ GINECO GROUPMerck Sharp & Dohme LLC; OSE ImmunotherapeuticsRecruitingRelapsed Ovarian Cancer | Platinum-sensitive Ovarian CancerBelgium, France, Germany
-
Array BioPharmaCompletedAML | Advanced and Selected Solid Tumors | High Risk and Very High Risk MDSUnited States, Australia, Italy, Spain, France, Switzerland, United Kingdom